By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
ZURAMPIC Drug Profile
Email this page to a colleague
Which patents cover Zurampic, and what generic alternatives are available?
Zurampic is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are nine patents protecting this drug.
This drug has one hundred and ninety-nine patent family members in forty-one countries.
The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.
DrugPatentWatch® Generic Entry Outlook for Zurampic
Zurampic was eligible for patent challenges on December 22, 2019.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 29, 2032. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for ZURAMPIC
| International Patents: | 199 |
| US Patents: | 9 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 73 |
| Patent Applications: | 191 |
| Drug Prices: | Drug price information for ZURAMPIC |
| DailyMed Link: | ZURAMPIC at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for ZURAMPIC
Generic Entry Date for ZURAMPIC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
ATC Classes for ZURAMPIC
US Patents and Regulatory Information for ZURAMPIC
International Patents for ZURAMPIC
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2011159732 | Try Before You Buy |
| Chile | 2008003529 | Try Before You Buy |
| World Intellectual Property Organization (WIPO) | 2010028189 | Try Before You Buy |
| South Korea | 101541629 | Try Before You Buy |
| Mexico | 2013007505 | Try Before You Buy |
| Japan | 5457472 | Try Before You Buy |
| Serbia | 52632 | Try Before You Buy |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ZURAMPIC
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2135608 | C02135608/01 | Switzerland | Try Before You Buy | PRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65925 07.04.2017 |
| 2135608 | 1690033-4 | Sweden | Try Before You Buy | PRODUCT NAME: LESINURAD, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REG. NO/DATE: EU/1/15/1080 20160222 |
| 2135608 | 288 5019-2016 | Slovakia | Try Before You Buy | PRODUCT NAME: LESINURAD VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/15/1080 20160222 |
| 2135608 | 34/2016 | Austria | Try Before You Buy | PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 (MITTEILUNG) 20160222 |
| 2135608 | 93169 | Luxembourg | Try Before You Buy | PRODUCT NAME: LESINURAD , OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION DATE: 20160222 |
| 2135608 | 300825 | Netherlands | Try Before You Buy | PRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222 |
| 2217577 | 7/2019 | Austria | Try Before You Buy | PRODUCT NAME: ALLOPURINOL UND LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER SALZE DAVON; REGISTRATION NO/DATE: EU/1/18/1300 20180827 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
